Tenofovir (tdf) and emtricitabine (ftc) (DrugBank: Emtricitabine, Tenofovir)
4 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
25 | 進行性多巣性白質脳症 | 0 |
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 0 |
265 | 脂肪萎縮症 | 0 |
325 | 遺伝性自己炎症疾患 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03304717 (ClinicalTrials.gov) | January 2021 | 4/8/2017 | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Aicardi Goutières Syndrome | Drug: Tenofovir (TDF) and Emtricitabine (FTC);Other: Placebo | Children's Hospital of Philadelphia | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Human Genome Research Institute (NHGRI);Gilead Sciences;Emerson Resources;National Institutes of Health (NIH) | Not yet recruiting | 2 Years | 18 Years | All | 34 | Phase 1;Phase 2 | United States |